Paediatric Neurology Care — Evidence-Based Treatment Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Paediatric neurology is the medical speciality dedicated to the diagnosis and management of disorders affecting the nervous system — brain, spinal cord, peripheral nerves, and muscles — in children from the neonatal period through to late adolescence. The breadth of conditions encountered is vast, encompassing epilepsy, neurodevelopmental disorders, headache syndromes, neuromuscular disease, neurometabolic conditions, and acquired brain injuries.

Neurological conditions are among the most common reasons children are referred to paediatric specialists. Epilepsy affects approximately 1 in 200 children in the UK; attention deficit hyperactivity disorder (ADHD) affects 3–5% of school-aged children; and headache is one of the top three complaints in paediatric emergency visits. Collectively, neurological and neurodevelopmental conditions account for a substantial proportion of childhood disability, making timely diagnosis and evidence-based management a priority.

The International League Against Epilepsy (ILAE) 2022 operational classification provides the current gold standard framework for classifying seizure types, epilepsy types (focal, generalised, combined, unknown), and epilepsy syndromes — a precision medicine approach that guides choice of antiepileptic drug (AED) therapy to maximise seizure control while minimising adverse effects specific to each syndrome.

Paediatric neurology is increasingly a multidisciplinary endeavour: neurologists work closely with neuropsychologists, speech and language therapists, educational psychologists, paediatric psychiatrists, neuroradiologists, and metabolic disease specialists to provide holistic, family-centred care. Early diagnosis and intervention for neurodevelopmental conditions such as ADHD and autism spectrum disorder (ASD) are strongly associated with improved long-term educational attainment, independence, and quality of life.

This guide covers the most clinically significant paediatric neurological conditions, emphasising evidence-based diagnosis and treatment grounded in current NICE, ILAE, and American Academy of Neurology (AAN) guidelines.

Paediatric neurologists evaluate and manage a wide spectrum of conditions affecting the developing nervous system, including:

• Epilepsy: Classified using the ILAE 2022 operational framework into focal onset, generalised onset, combined focal and generalised, and unknown onset seizures. Epilepsy syndromes — including childhood absence epilepsy, juvenile myoclonic epilepsy (JME), Dravet syndrome, Lennox-Gastaut syndrome, and self-limited epilepsy with centrotemporal spikes (SELECTS, formerly BECTS) — are defined by seizure type, EEG signature, age of onset, and prognosis, each with syndrome-specific AED recommendations.
• Febrile seizures: The most common convulsive disorder in childhood (affecting 2–5% of children aged 6 months to 5 years). Simple febrile seizures are brief (<15 minutes), generalised tonic-clonic, and occur once in a 24-hour period during fever — benign with no increased risk of epilepsy above the general population. Complex febrile seizures are prolonged (>15 minutes), focal in nature, or recur within 24 hours, and require more thorough investigation including EEG and MRI.
• ADHD (Attention Deficit Hyperactivity Disorder): Managed per NICE Guideline NG87 (ADHD: diagnosis and management). Core features are inattention, hyperactivity, and impulsivity causing functional impairment in two or more settings. ADHD is frequently comorbid with autism, anxiety disorders, dyslexia, and tic disorders, requiring coordinated neurodevelopmental assessment.
• Autism Spectrum Disorder (ASD): A neurodevelopmental condition characterised by persistent difficulties in social communication and restricted, repetitive patterns of behaviour. Prevalence is approximately 1 in 57 children (UK, 2023 data). Paediatric neurology contributes to multidisciplinary autism diagnostic assessment and manages associated epilepsy, sleep disorders, and challenging behaviours.
• Childhood headache: Migraine affects up to 10% of school-age children. The CHAMP (Childhood and Adolescent Migraine Prevention) trial demonstrated that amitriptyline and topiramate were not superior to placebo for migraine prevention in children and adolescents, resulting in updated management guidelines emphasising lifestyle measures and acute therapy. Cluster headache and intracranial hypertension (pseudotumour cerebri) are important secondary headache syndromes requiring specialist evaluation.
• Developmental regression: Loss of previously acquired developmental milestones is a red flag for serious underlying disease including mitochondrial disorders (e.g., MELAS, Leigh syndrome), lysosomal storage disorders (e.g., neuronal ceroid lipofuscinoses, Niemann-Pick disease), and autoimmune encephalitis. Urgent metabolic and autoimmune screening is mandatory.
• Neurodegenerative conditions: Including leukodystrophies (metachromatic leukodystrophy, adrenoleukodystrophy), neurodegeneration with brain iron accumulation (NBIA), and spinal muscular atrophy (SMA). Novel disease-modifying therapies (nusinersen, onasemnogene abeparvovec for SMA; gene therapy for ALD) have transformed previously fatal conditions.

Referral to a paediatric neurologist is indicated for any child with a suspected or confirmed neurological disorder that exceeds the diagnostic or management capacity of the referring paediatrician or GP. Specific indications for urgent or routine referral include:

• First seizure in a child: Any child presenting with a first unprovoked seizure should be referred to a paediatric neurologist within two weeks (NICE CG137: The Epilepsies). If the seizure is prolonged, focal, or associated with post-ictal neurological deficit (Todd's paresis), same-day MRI brain and same-day or next-day neurology review is recommended.
• Suspected epilepsy syndrome: Children with recurrent seizures, or paroxysmal events uncertain as to whether they represent epilepsy, should be seen within four weeks by a specialist with expertise in paediatric epilepsy, including access to video-EEG and epilepsy nurse specialist support.
• Developmental regression: Any child losing previously acquired motor, language, or cognitive milestones requires urgent investigation. This is a neurological emergency until proven otherwise, as many metabolic and autoimmune causes are treatable if diagnosed promptly. Urgent investigations include plasma and urine metabolic screen, autoimmune encephalitis antibody panel, MRI brain, and EEG.
• Suspected neurodevelopmental disorder: Children with features of ADHD, ASD, global developmental delay, or specific learning difficulties should be referred to a community paediatric neurodevelopmental team for structured multidisciplinary assessment. NICE NG87 recommends referral for ADHD assessment when features are present in two or more settings (home and school) and cause significant functional impairment.
• Headache requiring specialist evaluation: Red-flag headache features requiring urgent neuroimaging and specialist review include: new-onset headache in a child under 3 years, headache awakening the child from sleep, progressive headache worsening over days to weeks, headache with neurological signs (papilloedema, diplopia, ataxia), or headache associated with early-morning vomiting (suggesting raised intracranial pressure).
• Suspected neuromuscular disease: Hypotonia in a neonate, progressive weakness in a school-age child, or abnormal gait with muscle wasting requires electrophysiological and genetic investigation for conditions such as Duchenne muscular dystrophy, SMA, or hereditary neuropathies.

Treatment in paediatric neurology is highly individualised and syndrome-specific. Principal therapeutic modalities include:

• Antiepileptic drug (AED) therapy — syndrome-specific approach:
  • Self-limited epilepsy with centrotemporal spikes (SELECTS / former BECTS): Often requires no AED treatment given the self-limiting nature. If treatment is chosen, carbamazepine (400–800 mg/day in divided doses) is first-line; sulthiame is an alternative.
  • Childhood absence epilepsy (CAE): Sodium valproate (first-line in boys; restricted in girls of childbearing potential due to teratogenicity) or ethosuximide (equally effective for absences, no convulsive seizure protection); lamotrigine as second-line.
  • Juvenile myoclonic epilepsy (JME): Sodium valproate is the most effective agent (80–85% seizure freedom). Alternatives for females: levetiracetam, lamotrigine (less effective for myoclonus), topiramate. Lifelong AED treatment is usually required.
  • Dravet syndrome: Sodium valproate + clobazam as first-line; stiripentol (licensed add-on); cannabidiol (Epidyolex) and fenfluramine (Fintepla) for refractory cases. Carbamazepine and lamotrigine are contraindicated as they worsen Dravet.
  • Focal epilepsy: Lamotrigine or levetiracetam first-line (sodium valproate increasingly avoided in females); carbamazepine or oxcarbazepine for focal seizures with good tolerability.
• ADHD management (NICE NG87): In children aged 5 years and over: parent training and school-based behavioural interventions are offered first. Drug treatment is added when symptoms remain impairing: methylphenidate (first-line; immediate-release or modified-release) with structured monitoring of response, height, weight, and cardiovascular parameters. Alternatives: lisdexamfetamine (licensed from age 6), atomoxetine (non-stimulant), guanfacine. Review at 6 months and annually.
• Childhood migraine — acute treatment: Ibuprofen 10 mg/kg and paracetamol 15 mg/kg are first-line acute treatments. Oral sumatriptan nasal spray (licensed from age 12) or rizatriptan (from age 6 in some countries) for moderate-severe attacks. Preventive treatment: CHAMP trial evidence has reduced enthusiasm for topiramate and amitriptyline; lifestyle measures (sleep hygiene, regular meals, hydration, stress management) and propranolol (off-label in children) are used. Psychological therapies (CBT-based pain management) have the strongest evidence for prevention.
• Autoimmune encephalitis and developmental regression: Confirmed or suspected autoimmune encephalitis (anti-NMDAR, anti-LGI1, anti-CASPR2 antibodies) requires high-dose IV methylprednisolone, IV immunoglobulin (IVIG), and plasma exchange as first-line immunotherapy, with rituximab or mycophenolate for refractory or relapsing disease. Metabolic conditions identified by urine/plasma screen require specific metabolic therapies (dietary, enzyme replacement, gene therapy as available).
• Disease-modifying therapy for SMA: Nusinersen (intrathecal), onasemnogene abeparvovec (IV gene therapy, licensed to 2 years or <21 kg), and risdiplam (oral SMN2 splicing modifier) have transformed outcomes in spinal muscular atrophy when initiated early — ideally in the presymptomatic phase through newborn screening programmes.

Access to specialist paediatric neurology services is associated with meaningful improvements in seizure control, neurodevelopmental outcomes, quality of life, and safety for children with neurological conditions. Key benefits include:

• Accurate epilepsy syndrome diagnosis: Correct syndrome-specific AED prescribing (avoiding drugs that worsen specific syndromes, such as carbamazepine in Dravet) reduces the risk of seizure exacerbation, unnecessary polypharmacy, and drug-related adverse effects. NICE audits consistently show that AED prescribing by epilepsy specialists is safer and more effective than prescribing by non-specialists.
• Access to epilepsy surgery evaluation: Children with drug-resistant focal epilepsy (failure of two appropriate AEDs at adequate doses) are eligible for comprehensive presurgical evaluation — video-EEG telemetry, high-resolution MRI, neuropsychology, and functional imaging. Resective surgery achieves seizure freedom in 60–80% of carefully selected cases, with the prospect of AED withdrawal and normal neurodevelopmental trajectory.
• Earlier ADHD and ASD diagnosis: Timely specialist neurodevelopmental assessment accelerates access to school-based support, EHCP (Education, Health and Care Plan) provision in England, therapeutic interventions, and (for ADHD) pharmacological treatment. Early diagnosis and support are strongly associated with improved educational outcomes, reduced mental health comorbidity, and better quality of life for the child and family.
• Disease-modifying intervention in progressive conditions: Early identification of treatable progressive neurological conditions — autoimmune encephalitis, SMA (via newborn screening), neurometabolic disorders — enables timely initiation of disease-modifying therapies that can arrest or reverse neurological decline, which is impossible once irreversible neuronal loss has occurred.
• Family and caregiver support: Epilepsy nurse specialists, paediatric neurodevelopmental keyworkers, and specialist social workers provide essential support for families managing complex neurological conditions, improving medication adherence, reducing parental anxiety, and enabling children to participate in mainstream education and social activities.

All pharmacological and surgical interventions in paediatric neurology carry risks that must be carefully weighed against expected benefits and communicated to families in accessible language.

• Sodium valproate — teratogenicity risk: Sodium valproate carries a major risk of neural tube defects (1–2%), congenital malformations (10%), and neurodevelopmental impairment (30–40% of children exposed in utero have ASD or developmental delay). The MHRA Valproate Pregnancy Prevention Programme mandates that valproate should not be prescribed to girls and women of childbearing potential without specialist authorisation and a signed annual risk acknowledgement form. In boys, valproate remains a highly effective first-line AED for generalised epilepsy syndromes.
• Stimulant medications for ADHD: Methylphenidate and lisdexamfetamine may cause reduced appetite, sleep disturbance, headache, and abdominal pain in the short term. Long-term monitoring of height and weight is essential (stimulants modestly reduce growth velocity in some children during puberty). Cardiovascular monitoring — baseline pulse and blood pressure, ECG if clinically indicated — is required per NICE NG87. Stimulants do not increase the risk of substance use disorder in children with ADHD; treatment reduces overall risk.
• AED adverse effects: Each AED has a specific adverse effect profile. Levetiracetam is associated with behavioural changes and irritability (particularly in children with pre-existing neurodevelopmental conditions). Lamotrigine carries a small risk of Stevens-Johnson syndrome, particularly when dose-escalated too rapidly. Topiramate causes cognitive slowing, word-finding difficulties, and weight loss. Regular clinical review and blood level monitoring (for selected AEDs) are essential.
• Risk of sudden unexpected death in epilepsy (SUDEP): SUDEP affects approximately 1 in 1000 people with epilepsy per year; risk is highest in those with poorly controlled generalised tonic-clonic seizures. Families must be counselled about SUDEP risk and strategies to reduce it: optimising AED control, supervised nighttime care, avoiding alcohol (in adolescents), and ensuring safe sleep positioning.
• Misdiagnosis of epilepsy: Up to 30% of children referred with "epilepsy" do not have epileptic seizures — non-epileptic paroxysmal events (reflex anoxic seizures, syncope, psychogenic non-epileptic seizures) are commonly misdiagnosed and incorrectly treated with AEDs. Video-EEG documentation of a habitual event is the gold standard for diagnosis and avoids unnecessary long-term medication.

Long-term follow-up in paediatric neurology is essential for optimising seizure control, monitoring drug safety, tracking neurodevelopmental progress, and planning transitions to adult neurology services. Key components include:

Epilepsy follow-up:

• Children on AEDs should be reviewed at minimum every 6 months by a paediatric epilepsy specialist or epilepsy nurse specialist, assessing seizure frequency, AED tolerability, adherence, and impact on daily life and education
• Annual review should include discussion of contraception and valproate risk for adolescent girls; bone health monitoring for children on enzyme-inducing AEDs (carbamazepine, phenytoin — which reduce vitamin D levels); and SUDEP risk counselling for those with persisting tonic-clonic seizures
• Children achieving two years of seizure freedom on monotherapy may be considered for AED withdrawal, with a structured tapering plan and discussion of the 30–50% risk of relapse during or after withdrawal
• Repeat EEG is not routinely recommended solely on the basis of time; it is performed when there is a change in seizure type, suspected syndrome re-classification, or pre-surgical evaluation

ADHD follow-up (NICE NG87):

• At 4–6 weeks after initiating medication: assess response using validated rating scales (Conners, SNAP-IV), adverse effects, and titration needs
• At 3 months and then every 6 months: review height, weight, pulse, blood pressure, sleep, appetite, emotional wellbeing, and school functioning
• Annual face-to-face ADHD review by a specialist is recommended; medication holidays during school holidays may be considered for non-severe presentations

Developmental and neurodegenerative conditions:

• Structured developmental surveillance at each clinic visit using age-appropriate tools (Griffiths, Bayley, WPPSI/WISC-R)
• Annual MRI brain for children with progressive neurological conditions or unexplained developmental regression
• Transition planning from age 14 onwards for children with complex neurological needs, ensuring seamless handover to adult neurology, neurodisability, or transition clinics

The costs of paediatric neurology care vary significantly depending on the condition, diagnostic workup required, treatment chosen, and the healthcare system. Key cost drivers include:

• Diagnostic investigations: EEG costs approximately £200–£500 in the UK NHS. Video-EEG telemetry for prolonged inpatient monitoring costs £2,000–£10,000 per admission. High-resolution MRI brain with epilepsy protocol costs £500–£2,000. Genetic and metabolic panels for diagnostic workup in developmental regression may cost £500–£5,000 depending on the breadth of testing. Whole exome or genome sequencing is increasingly available through NHS Genomics and costs approximately £1,000–£3,000 per patient.
• Antiepileptic drugs: Generic AEDs (sodium valproate, carbamazepine, lamotrigine, levetiracetam) are inexpensive, typically costing £20–£100 per month. Newer licensed AEDs and orphan drugs for rare epilepsies carry substantially higher costs: cannabidiol (Epidyolex) for Dravet syndrome may cost £12,000–£30,000 per year. Fenfluramine (Fintepla) for Dravet syndrome costs approximately £40,000–£60,000 per year in the UK, accessed via NHS commissioning.
• ADHD medications: Generic methylphenidate costs approximately £20–£80 per month in the UK. Lisdexamfetamine (Vyvanse/Elvanse) and atomoxetine (Strattera) cost £80–£180 per month. ADHD medication costs are typically covered by NHS prescription in the UK with standard prescription charges.
• Disease-modifying therapies for rare conditions: Nusinersen (Spinraza) for SMA costs approximately £500,000 per patient in the first year and £250,000 annually thereafter (NHS negotiated price substantially lower via managed access agreements). Onasemnogene abeparvovec (Zolgensma) for SMA has a list price exceeding £1.79 million per patient — the most expensive drug in the world — though NHS access is available through a managed access scheme.
• Epilepsy surgery: Comprehensive presurgical evaluation (video-EEG telemetry, high-resolution MRI, neuropsychology, MEG, functional MRI, invasive EEG where needed) costs £15,000–£30,000. Resective surgery and PICU care may add £20,000–£50,000, with long-term savings through AED reduction and improved quality of life.

A range of non-pharmacological and complementary strategies play an important evidence-based role in paediatric neurology, either as adjuncts to medication or as primary treatment in specific conditions:

• Ketogenic diet therapy: A high-fat, low-carbohydrate, controlled-protein diet that produces ketosis, which has direct anticonvulsant effects. Licensed for use in drug-resistant epilepsy in children where two or more appropriate AEDs have failed. The modified Atkins diet (MAD) and low glycaemic index treatment (LGIT) are better-tolerated variants. Approximately 50% of children achieve >50% seizure reduction; 10–15% become seizure-free. The ketogenic diet is the treatment of choice for glucose transporter type 1 (GLUT1) deficiency syndrome and pyruvate dehydrogenase deficiency.
• Vagus nerve stimulation (VNS): A surgically implanted device that delivers intermittent electrical stimulation to the vagus nerve, reducing seizure frequency by 30–40% in approximately half of children with drug-resistant epilepsy who are not candidates for resective surgery. Battery replacement is required every 5–10 years. VNS is also used as adjunctive treatment in Lennox-Gastaut syndrome.
• Behavioural and psychological therapies for ADHD and ASD: NICE NG87 recommends parent training programmes (Triple P, Incredible Years) as first-line management for ADHD in children under 5 years, and as a component of all ages of management. For ASD, applied behaviour analysis (ABA), speech and language therapy, occupational therapy, and social skills training improve adaptive functioning and quality of life without pharmacological adverse effects.
• Pain management CBT for childhood migraine: Following the CHAMP trial findings (topiramate and amitriptyline no better than placebo for migraine prevention in children), cognitive-behavioural therapy (CBT)-based pain management programmes have been positioned as first-line preventive strategy, with strong evidence for reducing headache frequency and disability in school-aged children and adolescents.
• Neurodevelopmental and rehabilitation therapies: Physiotherapy, occupational therapy, speech and language therapy, and assistive technology (AAC devices for non-verbal children, communication apps) are core components of management for children with motor disorders, cerebral palsy, acquired brain injury, and neurodegenerative conditions, often provided via community paediatric neurodisability services.
• Neuromodulation: Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are under investigation for paediatric migraine, ADHD, and depression in adolescents, and are not yet recommended outside of clinical trials by NICE or AAN.